Related Experiment Video

Updated: Apr 17, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

13.0K

miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression

Wenjing Mu1, Chaobo Hu1, Haibin Zhang2

  • 1State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academic of Sciences, Shanghai 200031, China.

Cell Research
|February 21, 2015
PubMed

Insights

A novel microRNA (miRNA), miR-27b, sensitizes liver and kidney cancer cells to multiple anticancer drugs. This approach shows promise for personalized cancer therapy by targeting drug resistance pathways.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Liver and kidney cancers exhibit significant drug resistance due to complex, heterogeneous mechanisms.
  • Targeting single resistance pathways has yielded limited success in cancer treatment.
  • Personalized therapies addressing multiple resistance pathways offer a promising future direction.

Purpose of the Study:

  • To develop a novel therapeutic strategy combining microRNAs (miRNAs) with anticancer drugs to overcome drug resistance.
  • To identify specific miRNAs that can sensitize cancer cells to a broad range of chemotherapeutics.
  • To investigate the mechanisms by which miRNAs enhance drug response in specific cancer patient subgroups.

Main Methods:

  • A systems biology approach was employed to identify relevant miRNAs.
  • miR-27b's efficacy was evaluated in vitro and in vivo for sensitizing cancer cells to anticancer drugs.
  • Mechanistic studies focused on p53-dependent apoptosis and CYP1B1-mediated drug metabolism.
  • Patient subgroup analysis was performed based on p53 and CYP1B1 expression signatures.

Main Results:

  • miR-27b, a miRNA deleted in liver and kidney cancers, was identified as a sensitizer to multiple anticancer drugs.
  • miR-27b enhances drug response by promoting p53-dependent apoptosis and inhibiting CYP1B1-mediated drug detoxification.
  • The therapeutic effect of miR-27b was observed both in vitro and in vivo.
  • miR-27b demonstrated efficacy specifically in patients with wild-type p53 or high CYP1B1 expression.

Conclusions:

  • miR-27b represents a novel therapeutic agent that synergizes with anticancer drugs to improve treatment response.
  • This miRNA-based strategy offers a personalized approach for treating a defined subgroup of liver and kidney cancer patients.
  • Targeting miR-27b in combination with chemotherapy holds potential for overcoming drug resistance in specific cancer indications.

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.1K
An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

9.1K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.5K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
8.0K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
8.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K